

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奥赛图（北京）医药科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

VOLUNTARY ANNOUNCEMENT DEVELOPMENT OF LITIGATION

This announcement is made by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the **“Company”** or **“Biocytogen”**) to provide its shareholders and potential investors with information on the latest development of the Company.

The board (the **“Board”**) of directors (the **“Director(s)”**) of the Company announces that, in relation to the allegation made by Harbour Antibodies B.V. (**“HBM”**), a group member company of HBM Holdings Limited (a biopharmaceutical company listed on the The Stock Exchange of Hong Kong Limited, stock code: 2142) on September 4, 2024 that the Company's RenNano platform along with the antibody products obtained from such platform has infringed its exclusively licensed invention patent ZL201210057668.0, the Shanghai Intellectual Property Court has made a first-instance judgment, dismissing the litigation claims brought by the plaintiff, HBM.

As an international biotechnology company driven by innovative technologies for the research and development of new drugs, Biocytogen highly values, protects its own intellectual property rights and respects and maintains the intellectual property rights of others. The Company has full confidence in its independently developed intellectual property rights, and will continue to maintain research and development investment, persist in driving business growth through independent innovation and research and development, and is committed to becoming a global source of new drugs.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Shen Yuelei

Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, June 29, 2026

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian as executive Director; Dr. Zhou Kexiang, Ms. Zhang Leidi and Dr. Liu Hongkang as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors; and Ms. Li Yan as employee Director.